Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

ABIOMED (ABMD) To Report Q3 Earnings: What's In The Offing?

By Zacks Investment ResearchStock MarketsJan 30, 2020 10:44PM ET
www.investing.com/analysis/abiomed-abmd-to-report-q3-earnings-whats-in-the-offing-200503666
ABIOMED (ABMD) To Report Q3 Earnings: What's In The Offing?
By Zacks Investment Research   |  Jan 30, 2020 10:44PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
+0.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
COR
+0.59%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABMD
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DXCM
+5.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
HQY
-1.89%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABIOMED, Inc. (NASDAQ:ABMD) is scheduled to release third-quarter fiscal 2020 results on Feb 6, before market opens. We believe that despite the persistent foreign currency woes, solid Impella product line prospects are expected to reflect on the results.
ABIOMED delivered an earnings surprise of 10.8% in the last reported quarter, the trailing four-quarter earnings surprise being a positive 3.7%, on average.
Q3 Estimates Picture
The Zacks Consensus Estimate for ABIOMED’s third-quarter earnings per share is pegged at $1.09, indicating a year-over-year improvement of 12.4%.
Let’s see how things are shaping up prior to the earnings release.
Impella Likely to Drive Q3 Results
ABIOMED’s flagship product line, Impella, has consistently boosted the company’s top line. Impella, a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart, is expected to have driven fiscal third-quarter earnings as well.
Notably, the treatment success rates of ABIOMED’s SmartAssist, Impella Connect, IQ Impella Quality Assurance Database and Impella 5.0 is expected to reflect in the quarterly results.
Apart from these, the recent post-approval studies for Impella 5.5 have received a nod from the FDA, which signifies increasing adoption of the device. Additionally, recent FDA approval of the Impella 5.5 with SmartAssist and plans to launch the same in the United States also buoy optimism. Moreover, Impella 2.5 and CP with SmartAssist are currently much in demand.
Notably, ABIOMED’s preliminary results project U.S. patient usage growth of 16% year over year and international growth of 24%. U.S. revenues are expected to have grown 8% year over year to $185.6 million. Internationally, revenues are estimated at $36.0 million, suggesting a 29% year-over-year rise on strength in Germany and Japan.
Thus, quarterly revenues are anticipated at $221.6 million, suggesting a 10% year-over-year rise but the metric is expected to lag the consensus mark.
Resultantly, the company slashed its fiscal 2020 revenue guidance.
Revenues are now expected within $846-$877 million, indicating an increase of 10-14% year over year. This compares to the earlier projected range of $885-$925 million, calling for a 15-20% rise year over year.
However, ABIOMED faces stiff competition in the global MedTech space and fluctuations in currency exchange rates.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is not the case here as you will see below.
Earnings ESP: ABIOMED has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
DexCom (NASDAQ:DXCM) has an Earnings ESP of +17.07% and a Zacks Rank #2.
AmerisourceBergen (NYSE:ABC) has an Earnings ESP of +0.82% and a Zacks Rank #3.
HealthEquity (NASDAQ:HQY) has an Earnings ESP of +18.56% and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>



ABIOMED, Inc. (ABMD): Free Stock Analysis Report

DexCom, Inc. (DXCM): Free Stock Analysis Report

AmerisourceBergen Corporation (ABC): Free Stock Analysis Report

HealthEquity, Inc. (HQY): Free Stock Analysis Report

Original post

Zacks Investment Research
ABIOMED (ABMD) To Report Q3 Earnings: What's In The Offing?
 

Related Articles

ABIOMED (ABMD) To Report Q3 Earnings: What's In The Offing?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email